Welcome to our dedicated page for Aquestive Therapeutics SEC filings (Ticker: AQST), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Aquestive Therapeutics, Inc. filings document the regulatory, financial, governance, and capital-structure disclosures of a specialty pharmaceutical company built around oral-film drug delivery, proprietary product candidates, and CDMO/licensee manufacturing. Its 8-K reports include FDA communications and Regulation FD materials for Anaphylm™, financial results, investor presentations, and material agreements related to revenue-sharing, warrants, and common-stock purchase commitments.
Proxy materials describe annual-meeting voting matters, director elections, executive compensation, auditor ratification, and board governance. Other current reports record officer-transition matters, compensatory arrangements, exhibits, and product-development updates tied to the company’s regulatory strategy.
Aquestive Therapeutics reported new human factors and pharmacokinetic data for Anaphylm™ (dibutepinephrine) sublingual film, supporting a planned resubmission of its New Drug Application for treatment of Type 1 allergic reactions, including anaphylaxis, in the third quarter of 2026. The company also furnished an investor presentation and a detailed press release describing these results.
In a 105-participant human factors validation study using revised packaging and instructions for use, median time to open the first pouch dropped to 3 seconds from 17 seconds in a prior study, while participants with difficulty opening the pouch fell from 26 of 166 to 1 of 105. Incorrect film placement decreased from 20 of 166 to 2 of 105, with no cases of chewing or removing the film. In a PK study, self-administered Anaphylm achieved a geometric mean Cmax of 391.7 pg/mL with a median Tmax of 12 minutes, comparable to clinician-administered Anaphylm and manual intramuscular epinephrine. Purposeful misplacement on top-of-tongue produced a geometric mean Cmax of 112.7 pg/mL, a median Tmax of 35 minutes, and clinically meaningful pharmacodynamic responses. No serious adverse events or discontinuations were reported, and the company is also advancing regulatory submissions for Anaphylm in Canada, the UK and the European Union.
BlackRock, Inc. filed an amended Schedule 13G reporting its beneficial ownership in Aquestive Therapeutics, Inc. common stock. BlackRock reports beneficial ownership of 7,992,647 shares, representing 6.4% of the outstanding common stock.
BlackRock has sole voting power over 7,885,637 shares and sole dispositive power over 7,992,647 shares, with no shared voting or dispositive power. Various underlying clients have rights to dividends or sale proceeds, but no individual client holds more than 5% of the outstanding common shares.
Daniel Barber, President and CEO of Aquestive Therapeutics, sold a total of 25,000 shares of common stock in open-market or private transactions on July 15–16, 2026, at prices between $4.00 and $4.04 per share, under a Rule 10b5-1 trading plan, and now directly holds 610,574 shares.
Daniel R. Barber submitted a notice relating to Aquestive Therapeutics (AQST) common stock, indicating an intention to sell 25,000 shares through Morgan Stanley Smith Barney LLC on or after 07/15/2026 on NASDAQ. These shares trace to 25,000 Restricted Stock Units acquired from the issuer on 03/09/2024. Over the prior three months, transactions labeled as 10b5-1 Sales show sales of 25,000 shares on 06/15/2026 and 8,257 shares on 05/15/2026, for amounts of 104010.00 and 35413.45, respectively.
Aquestive Therapeutics filed a resale prospectus registering 230,271 shares of Common Stock (the “Warrant Shares”) for resale by selling stockholders under a shelf registration. The Warrant Shares are issuable upon exercise of warrants issued in connection with a Tranche A term loan; the warrants are exercisable beginning May 12, 2026 and expire May 12, 2031.
The warrants carry an exercise price of $4.18 per share (Tranche A VWAP) and include a 4.99% beneficial ownership limitation (9.99% possible after notice and a 61-day delay). Aquestive is not selling any shares here and will only receive cash proceeds if warrants are exercised for cash; cashless exercises yield no proceeds to the company.
Aquestive Therapeutics files a resale prospectus registering up to 230,271 shares of Common Stock (the “Warrant Shares”) for resale by selling stockholders. The Warrant Shares are issuable upon exercise of warrants issued in connection with a $55.0M Tranche A term loan under a credit facility of up to $150.0M. The warrants have an exercise price of $4.18 per share (the Tranche A VWAP), became exercisable on May 12, 2026 and expire on May 12, 2031. Holders may elect cash or cashless exercise; the Company will receive cash proceeds only on cash exercises. The warrants include a Beneficial Ownership Limitation of 4.99% (or 9.99% if elected, effective 61 days after notice). The prospectus registers resale by multiple Oaktree-related selling stockholders and notes 125,466,988 shares outstanding as of June 18, 2026.
Aquestive Therapeutics director Julie Krop exercised and sold company stock under a pre-set trading plan. On June 23, 2026, she exercised options for 25,000 shares of common stock at $0.7132 per share, then sold 25,000 shares at an average price of $5.0157 in an open-market transaction.
Both the option exercise and the sale were carried out pursuant to a previously adopted Rule 10b5-1 trading plan. Following these transactions, the filing shows 0 shares of common stock held directly and no remaining listed derivative positions.
Aquestive Therapeutics President and CEO Daniel Barber reported an open-market sale of 25,000 shares of common stock. The shares were sold at a weighted average price of $4.1604 per share, within a range from $4.14 to $4.235 per share.
After this transaction, Barber directly holds 635,574 shares of Aquestive Therapeutics common stock.